Eterna Therapeutics
ERNA
44 hedge funds and large institutions have $47.3M invested in Eterna Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
38% more funds holding
Funds holding: 32 → 44 (+12)
17% more call options, than puts
Call options by funds: $3.21M | Put options by funds: $2.75M
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
40% less capital invested
Capital invested by funds: $78.3M → $47.3M (-$31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$777K |
| 4 |
State Street
Boston,
Massachusetts
|
+$691K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$604K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.99M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$950K |
| 3 |
DY
Dowling & Yahnke
San Diego,
California
|
-$285K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$270K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$173K |
ERNA Hedge Fund Activity: Q3 2021 in Review
44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2021, worth a combined $47.3M — down 40% from $78.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ERNA positions and 4 closed out — a net gain of 12 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $4.4M. The largest seller was Nuveen, cutting an estimated $1.99M.
- 44 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2021, up from 32 in Q2 2021.
- Funds reported $47.3M of Eterna Therapeutics stock for Q3 2021, down 40% quarter-over-quarter.
- 16 funds opened new Eterna Therapeutics positions in Q3 2021 and 4 closed out, a net change of +12 holders.
- The largest Eterna Therapeutics buyer in Q3 2021 was BlackRock, an estimated $4.4M added.
- The largest Eterna Therapeutics seller in Q3 2021 was Nuveen, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2021.